"Seit 1997 steht das Luisenkrankenhaus Düsseldorf für professionelle Medizin und intensive Pflege. Wir sind eine Spezialklinik für Senologie und Brustkrebs-Behandlung. Unsere Chefärztinnen Dr. Darsow & Dr. Möller und ihr Team schöpfen aus langjährigen Erfahrungen und über 700 Behandlungen pro Jahr. Neben Expertise und Erfahrung legen wir Wert auf die Qualität des Aufenthalts: Unsere Patientinnen und Patienten schätzen die familiäre Atmosphäre, die auf 4-Sterne-Hotelniveau ausgestatteten Zimmer, höchsten ärztlichen und pflegerischen Einsatz und bewerten all dies regelmäßig mit Bestnoten."

During the past decade, Luisenkrankenhaus GmbH & Co. KG., Brustzentrum conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 4 clinical trials were completed, i.e. on average, 200% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Luisenkrankenhaus GmbH & Co. KG., Brustzentrum" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "Breast International Group" with 1 trials sponsored, "German Breast Group" with 1 trials sponsored, "NSABP Foundation Inc" with 1 trials sponsored and "Puma Biotechnology, Inc." with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Luisenkrankenhaus GmbH & Co. KG., Brustzentrum" #1 collaborator was "Genentech, Inc." with 2 trials as a collaborator, "Breast European Adjuvant Studies Team" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Cancer International Research Group (CIRG)" with 1 trials as a collaborator and "Frontier Science & Technology Research Foundation, Inc." with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "Luisenkrankenhaus GmbH & Co. KG., Brustzentrum" are "Breast Cancer" (4 trials), "Metastatic Breast Cancer" (1 trials), "Primary Breast Cancer" (1 trials) and "Triple-negative Breast Cancer" (1 trials). Many other conditions were trialed in "Luisenkrankenhaus GmbH & Co. KG., Brustzentrum" in a lesser frequency.

Most popular intervention types in "Luisenkrankenhaus GmbH & Co. KG., Brustzentrum" are "Drug" (6 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Cyclophosphamide" (3 trials), "5-Fluorouracil" (2 trials), "Carboplatin" (2 trials), "Docetaxel" (2 trials) and "Doxorubicin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Luisenkrankenhaus GmbH & Co. KG., Brustzentrum" are 4 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Luisenkrankenhaus GmbH & Co. KG., Brustzentrum". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Luisenkrankenhaus GmbH & Co. KG., Brustzentrum, 1 suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Luisenkrankenhaus GmbH & Co. KG., Brustzentrum, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".